Author of

• 12418

  +

  P3.05 - Poster Session 3 - Preclinical Models of Therapeutics/Imaging (ID 159)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12432

    +

    P3.05-015 - Positron-emission tomography-computed tomography with the glucose analogue [18F] fluorodeoxyglucose in orthotopic implantation SCID mouse model of lung cancer (ID 2619)

    09:30 - 09:30  |  Author(s): A.M. Mohammed
    • Abstract

    Background
    In vivo evaluation is essential for development of lung cancer treatment. However, the subcutaneous xenograft models are not closely reproducing microenvironment of lung cancer. Although orthotopic implantation SCID mouse model of lung cancer presents lymphatic metastasis to mediastinum or pleuritis carcinomatosa with progression of disease, it has been difficult to evaluate the efficacy of treatment without sacrifice of model mouse. Positron-emission tomography-computed tomography (PET-CT) with the glucose analogue [18F] fluorodeoxyglucose (FDG) has been recently applied for evaluating tumor response to anticancer therapy. We have evaluated the utility of FDG PET-CT in orthotopic implantation SCID mice model of lung cancer.

    Methods
    Animals: 6 weeks male SCID mice (n=12). Cell line: Ma44-3 cloned from Ma44 (human squamous cell lung cancer cell line). Under sufficient anesthesia, mice were placed in the left lateral decubitus position. A 1-cm transverse incision was made in the right lateral skin just below the inferior border of the scapula. After intercostal muscles were exposed, 2 x 10[6] tumor cells/ml with 400 μg/ml Matrigel® was injected into the right lung in a volume of 10 μl (2.0x10[4 ]cells) of medium. Four or 5 days after implantation (6 mice on day 4 and other 6 mice on day 5), the SCID mice were examined with FDG PET-CT and mice whose lung tumors were identified were randomized to treatment group and control group. Treatment group mice received intraperitoneal injection of cisplatin (7mg/kg) on day 6 after implantation. All mice were examined with FDG PET-CT on day 8 and 13 after implantation. Tumor volume and maximal standardized uptake value (SUV max) of the lung tumor were calculated for all mice. All SCID mice were sacrificed on day 13 after implantation for histopathologic analysis.

    Results
    Six mice whose lung tumors were identified at the first FDG PET-CT were randomized to treatment group (n=3) and control group (n=3). The average growth rates (day 13 versus day 5 or 6) of tumor volume and SUV max of the treatment group were 144% and 108%, respectively, whereas the average growth rates of tumor volume and SUV max of the control group were 1470% and 271%, respectively.

    Conclusion
    Tumor growth and inhibition were evaluated by FDG PET-CT in orthotopic implantation SCID mice model of lung cancer. This in vivo evaluation system is useful for development of lung cancer treatment.